Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma - PubMed (original) (raw)

Zhijia Fan et al. Technol Cancer Res Treat. 2022 Jan-Dec.

Abstract

Background: Increasing numbers of studies reported platelet (PLT)- related measures could play a creative role in many malignancies, while the prognostic impact of these measures in hepatocellular carcinoma (HCC) remains limited and controversial. It is worth exploring the predictive value of PLT-related measures in HCC. Methods: A total of 279 HCC patients with hepatectomy were analyzed in the retrospective cohort study. The optimal cut-off points of these PLT-related indices were obtained by the receiver operating characteristic (ROC) curve. The associations of these indices with clinical characteristics and overall survival (OS) were evaluated by Kaplan-Meier curves and Cox proportional hazards models. Results: High PLT count and low prognostic nutritional index (low-PNI) were significantly associated with larger tumor size. The low gamma-glutamyl transpeptidase-to-platelet ratio (low-GPR) group was inclined to more hepatitis infections. Survival curves indicated that preoperative high-PLT, low-GPR, and low-PNI had a worse prognosis after surgery in the cohort. In addition, PLT≥220 × 109/L (HR, 2.274; 95% CI, 1.061-4.876; P = .035), PNI≥51.9 (HR, 0.503; 95% CI, 0.265-0.954; P = .035), and GPR≥0.2 (HR, 0.432; 95% CI, 0.204-0.912; P = .028) were identified as independent prognostic factors for survival outcomes in the multivariable analysis. Conclusion: High-PLT, low-GPR, and low-PNI as the preoperative predictors were associated with poor OS in HCC patients with hepatectomy. Our data reveal that they could be simple, easily obtained, and effective predictors for evaluation of survival outcomes in patients.

Keywords: blood platelets; gamma-glutamyl transpeptidase-to-platelet ratio; hepatocellular carcinoma; prognosis; prognostic nutritional index.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.

Figure 1.

Comparison of overall survival (OS) by Kaplan–Meier curve analysis in the cohort. Patients after surgery were stratified based on (A) platelet count (PLT), (B) gamma-glutamyl transpeptidase-to-platelet ratio (GPR), and (C) prognostic nutritional index (PNI).

Figure 2.

Figure 2.

Comparison of overall survival (OS) by Kaplan–Meier curve analysis in the cohort with propensity score matching analysis. Patients after surgery were stratified based on (A) platelet count (PLT) and (B) gamma-glutamyl transpeptidase-to-platelet ratio (GPR).

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res. 2018;30(6):571-579. doi: 10.21147/j.issn.1000-9604.2018.06.01 - DOI - PMC - PubMed
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018;391(10127):1301-1314. doi: 10.1016/s0140-6736(18)30010-2 - DOI - PubMed
    1. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology. 2012;55(2):476-482. doi: 10.1002/hep.24710 - DOI - PMC - PubMed
    1. Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett. 2018;412:283-288. doi: 10.1016/j.canlet.2017.10.008 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources